INBX
Inhibrx Biosciences, Inc.
NASDAQ: INBX · HEALTHCARE · BIOTECHNOLOGY
$124.82
-4.47% today
Updated 2026-04-29
Market cap
$1.82B
P/E ratio
—
P/S ratio
1,402.52x
EPS (TTM)
$-9.04
Dividend yield
—
52W range
$11 – $155
Volume
0.3M
Inhibrx Biosciences, Inc. (INBX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.67M | $7.95M | $7.50M | $9.09M | $12.81M | $7.13M | $2.19M | $1.80M | $200000.00 | $1.30M |
| Revenue growth (YoY) | — | +19.2% | -5.7% | +21.2% | +40.9% | -44.4% | -69.2% | -17.9% | -88.9% | +550.0% |
| Cost of revenue | $16.99M | $25.51M | $33.45M | $47.91M | $73.50M | $2.69M | $110.19M | $1.19M | $2.29M | $2.48M |
| Gross profit | $-10.32M | $-17.56M | $-25.95M | $-38.81M | $-60.69M | $4.44M | $-107.99M | $609000.00 | $-2.08M | $-1.18M |
| Gross margin | -154.9% | -220.9% | -346.1% | -426.9% | -473.8% | 62.3% | -4926.7% | 33.8% | -1042.5% | -91.0% |
| R&D | $16.99M | $25.51M | $33.45M | $47.91M | $73.50M | $71.44M | $110.19M | $190.65M | $203.74M | $113.03M |
| SG&A | $1.82M | $2.61M | $4.65M | $9.02M | $6.84M | $12.36M | $21.12M | $29.38M | $127.91M | $23.30M |
| Operating income | $-12.15M | $-19.73M | $-29.51M | $-43.71M | $-67.44M | $-76.56M | $-129.12M | $-219.22M | $-331.45M | $-135.03M |
| Operating margin | -182.2% | -248.2% | -393.5% | -480.7% | -526.6% | -1074.6% | -5890.4% | -12178.9% | -165724.0% | -10386.5% |
| EBITDA | $-11.89M | $-19.30M | $-28.77M | $-42.60M | $-63.80M | $-75.37M | $-125.82M | $-206.69M | $1.70B | $-132.54M |
| EBITDA margin | -178.4% | -242.8% | -383.6% | -468.5% | -498.1% | -1057.8% | -5739.8% | -11482.9% | 851675.0% | -10195.5% |
| EBIT | $-12.15M | $-19.70M | $-29.45M | $-45.12M | $-64.82M | $-76.56M | $-127.04M | $-207.88M | $1.70B | $-135.03M |
| Interest expense | — | $2.13M | $1.48M | $5.72M | $10.82M | $5.22M | $16.11M | $31.84M | $13.49M | $12.20M |
| Income tax | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-8.27M | $-19.44M | $-31.16M | $-51.40M | $-75.64M | $-81.77M | $-145.23M | $-241.36M | $1.69B | $-140.06M |
| Net income growth (YoY) | — | -135.1% | -60.3% | -64.9% | -47.2% | -8.1% | -77.6% | -66.2% | +799.2% | -108.3% |
| Profit margin | -124.0% | -244.6% | -415.5% | -565.3% | -590.5% | -1147.6% | -6625.3% | -13408.9% | 843786.0% | -10773.5% |